A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma
Peter Martin(Northwestern University), John P. Leonard(New York University), John N. Allan(Cornell University), Jia Ruan(Cornell University), Xiangao Huang(Cornell University), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Zhengming Chen(Cornell University), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Maurizio DiLiberto(NewYork–Presbyterian Hospital), Richard R. Furman(Cornell University)
Cited by 27
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k